PDCD1 and focal segmental glomerulosclerosis: Finally, specifically antagonizing the PD-1 pathway with a specific anti–PD-1 antibody (similar to humanized pembrolizumab or nivolumab) in aged mice and mice with experimental FSGS had major benefits on kidney histology, podocyte life and health span, and tubular epithelial injury (2).